A Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Failed First-Line Dacabazine or Temozolomide Contained Therapy

Inclusion Criteria: * Patients with histologically proven malignant melanoma (recurred or metastatic) that had progressed during or after receiving at least one cycle of a regimen containing dacarbazine or temozolomide in the advanced setting * Measurable disease (RECIST) * ECOG performance 0-2 * Adequate organ function * Total bilirubin \<1.5N ; ASAT and ALAT \<2.5N * Serum Creatinin \< 1.5N * ANC ≥ 1,500/mm³ (G-CSF allowed) * Platelets ≥ 100,000/mm³ * Hb ≥ 9.0 g/dL * Life expectancy of at least 12 weeks * Signed Written Informed Consent Exclusion Criteria: * Symptomatic brain metastasis * Previous history of treatment with taxane or platinum agent containing chemotherapy * Previous major surgery within 2 weeks before the start of the trial, or a failure to recover from the surgery * Previous history of other malignancies within 5 years except for cured skin basal cell carcinoma or cured in-situ cervix cancer * Other severe medical conditions (infection, uncontrolled hypertension, heart failure, MI history within 6 months) * Sensitivity to platinum agents or docetaxel * Uncontrolled seizure * Women pregnant or nursing * Alcohol or drug abuser